On October 21, 2024, Galmed Pharmaceuticals Ltd. announced that its shareholders approved a proposal related to a Standby Equity Purchase Agreement, increasing the commitment to $20 million. The agreement allows the company to sell shares over the next three years, increasing from an initial $10 million commitment.